349 related articles for article (PubMed ID: 12593629)
1. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Yang Y; Li Q; Yang T; Hussain M; Shuaib A
J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
[TBL] [Abstract][Full Text] [Related]
2. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
[TBL] [Abstract][Full Text] [Related]
3. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
[TBL] [Abstract][Full Text] [Related]
5. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
Romanos E; Planas AM; Amaro S; Chamorro A
J Cereb Blood Flow Metab; 2007 Jan; 27(1):14-20. PubMed ID: 16596120
[TBL] [Abstract][Full Text] [Related]
6. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
[TBL] [Abstract][Full Text] [Related]
7. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
El Amki M; Lerouet D; Coqueran B; Curis E; Orset C; Vivien D; Plotkine M; Marchand-Leroux C; Margaill I
Exp Neurol; 2012 Dec; 238(2):138-44. PubMed ID: 22921458
[TBL] [Abstract][Full Text] [Related]
8. Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke.
Tanaka Y; Marumo T; Omura T; Yoshida S
Brain Res; 2007 Jun; 1154():194-9. PubMed ID: 17475227
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
Allahtavakoli M; Shabanzadeh A; Roohbakhsh A; Pourshanazari A
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):309-14. PubMed ID: 17910613
[TBL] [Abstract][Full Text] [Related]
10. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Zhang L; Zhang ZG; Liu X; Hozeska A; Stagliano N; Riordan W; Lu M; Chopp M
Thromb Haemost; 2006 Jan; 95(1):166-73. PubMed ID: 16543976
[TBL] [Abstract][Full Text] [Related]
11. Improved perfusion with rt-PA and hirulog in a rabbit model of embolic stroke.
Yenari MA; de Crespigny A; Palmer JT; Roberts S; Schrier SL; Albers GW; Moseley ME; Steinberg GK
J Cereb Blood Flow Metab; 1997 Apr; 17(4):401-11. PubMed ID: 9143222
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapies using normobaric oxygen with hypothermia or ethanol for reducing hyperglycolysis in thromboembolic cerebral ischemia.
Cai L; Stevenson J; Peng C; Xin R; Rastogi R; Liu K; Geng X; Gao Z; Ji X; Rafols JA; Ji Z; Ding Y
Neuroscience; 2016 Mar; 318():45-57. PubMed ID: 26794589
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human tissue plasminogen activator protects the basal lamina in experimental focal cerebral ischemia.
Burggraf D; Martens HK; Jäger G; Hamann GF
Thromb Haemost; 2003 Jun; 89(6):1072-80. PubMed ID: 12783121
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model.
Lekieffre D; Benavides J; Scatton B; Nowicki JP
Brain Res; 1997 Nov; 776(1-2):88-95. PubMed ID: 9439799
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Grotta J;
Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
Jiang Q; Zhang RL; Zhang ZG; Ewing JR; Divine GW; Chopp M
J Cereb Blood Flow Metab; 1998 Jul; 18(7):758-67. PubMed ID: 9663506
[TBL] [Abstract][Full Text] [Related]
17. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
Okubo S; Igarashi H; Kanamatsu T; Hasegawa D; Orima H; Katayama Y
Brain Res; 2007 Apr; 1143():221-7. PubMed ID: 17316578
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study.
Kollmar R; Henninger N; Bardutzky J; Schellinger PD; Schäbitz WR; Schwab S
Exp Neurol; 2004 Nov; 190(1):204-12. PubMed ID: 15473993
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Ma Y; Li L; Niu Z; Song J; Lin Y; Zhang H; Du G
Pharmacol Res; 2016 May; 107():291-299. PubMed ID: 27038532
[TBL] [Abstract][Full Text] [Related]
20. Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging.
Dijkhuizen RM; Asahi M; Wu O; Rosen BR; Lo EH
J Cereb Blood Flow Metab; 2001 Aug; 21(8):964-71. PubMed ID: 11487732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
